Deborah K. Armstrong, M.D.

 

Co-PI, Developmental Research Program

Co-Investigator, Project 6

 


Education/Training
University of California

Berkeley, CA.

A.B. (Bacteriology), 1975


George Washington University School of Medicine

Washington, DC.

M.D., 1984


University of Pittsburgh

Pittsburgh, PA.

Resident in Internal Medicine, 1984-1987.


University of Pittsburgh

Pittsburgh, PA.

Chief Resident in Internal Medicine, 1987-1988.


The Johns Hopkins University School of Medicine

Baltimore, MD.

Fellow in Oncology, 1988-1993.



Professional Experience


1987-1988


Instructor in Medicine, Chief Medical Resident, University or Pittsburgh, Department of Internal Medicine


1993-1994


Instructor in Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD


1993-1994


Instructor in Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD


1993-


Active Staff, Oncology, The Johns Hopkins Hospital, Baltimore, MD


1993-


Principal Investigator, Gynecologic Oncology Group


1994-


Assistant Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD


1994-


Ovarian Committee, Gynecologic Oncology Group


1996


National Institutes of Health, Office of Research on Women’s Health. Scientific Issues for Women’s Health Research: Cancer Working Group

 


National Institutes of Health, General Clinical Research Center site visit reviewer (ad hoc)


1998-


National Comprehensive Cancer Network, Ovarian Cancer Panel


1998-


National Comprehensive Cancer Network, Bone Marrow Transplant Panel


1998-


Developmental Therapeutics Committee, Gynecologic Oncology Group


1998-


Phase I Committee, Gynecologic Oncology Group


1999,2000


Department of Defense Breast Cancer Research Program Peer Review Panel


2000-


Assistant Professor of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD


Selected Publications
Arieff AI, Cooper JD, Armstrong DK, Lazarowitz VC: Dementia, renal failure, and brain aluminum. Ann Intern Med 1979;90:741-47.

McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-79.

Armstrong DK, Ettinger DS: Current approaches to treatment of hypercalcemia of malignancy. Mod Med 1990;45:226-31.

Armstrong DK, Gordon GB, Hilton J, Colvin OM, Davidson NE: Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. Cancer Res 1992;52:1416-21.

Armstrong DK, Isaacs JT, Ottaviano YL, Davidson NE: Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res 1992;52:3418-24.

Armstrong DK, Fetting JH, Davidson NE, Gordon GB, Huelskamp AM, Abeloff MD: Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 1993;28:277-84.

May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE: Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 in association with suppression of apoptosis. J Biol Chem 1994;43:26865-70.

Armstrong DK, Kaufmann SH, Ottaviano YL, Furuya Y, Buckley JA, Isaacs JT, Davidson NE: Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994;54:5280-83.

Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen TL, Davidson NE: Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 1995;13:1136-43.

McCloskey DE, Armstrong DK, Jackisch C, Davidson NE: Programmed cell death in human breast cancer cells. Recent Prog Horm Res 1996;51:493-508.

O'Reilly S, Fleming GF, Baker S, Walczak JR, Bookman MA, McGuire III WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky ER: A phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a gynecologic oncology group study. J Clin Oncol 1997;15:177-86.

Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky E: Altered formation of topotecan-stabilized topoisomerse I-DNA adducts in human leukemia cells. Blood 1997;89:2098-104.

ten Bokkel Huinink W, Carmichael J, Armstrong DK, Gordon A, Malfetano J: Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol 1997;24(Suppl 5):19-25.

O'Reilly S, Armstrong DK, Grochow LB: Life threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecol Oncol 1997;67:329-30.

Armstrong DK, O'Reilly S: Clinical guidelines for managing topotecan related hematologic toxicity. Oncologist 1998;3:4-10.

Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M, Donehower R, Burks KA, Armstrong DK, Burke PJ, Grever MR, Kaufmann SK: A phase II window study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res 1998;4:2677-89.

Kottke TJ, Blajeski AL, Martins AL, Mesner, Jr. PW, Davidson NE, Earnshaw WC, Armstrong DK, Kaufmann SH: Comparison of paclitaxel, 5-fluoro-2'-deoxyuridine- and epidermal growth factor-induced apoptosis: evidence for EGF-induced anoikis. J Biol Chem 1999;274(22):15927-36.

Hahm HA, Armstrong DK, Chen TL, Grochow LB, Goodman SN, Davidson NE, Kennedy MJ: Phase II study of the alkylating agent modulator novobiocin in combination fith high dose chemotherapy for the treatment of advanced breast cancer. Biol Blood Marrow Transplant 2000;6(3A):335-43.

Armstrong DK, Davidson NE: Dose intensity for breast cancer. (In press, 2000).

 
 

 

 

 

Project 6

 

 

Investigators

 

T.-C. Wu

Debbie Armstrong

Maura Gillison

Martin Pomper

Chien-Fu Hung

 

Personnel

 

Ya-Chea Tsai

Irena Tartokovsky

Caroline Fidyk

 

 

 

 

Copyright © 2004 The Johns Hopkins University. All rights reserved.